Overview
Study Evaluating IMA-638 in Asthma
Status:
Completed
Completed
Trial end date:
2007-04-01
2007-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the safety of, and blood drug levels for, single, ascending doses of IMA-638 in mild to moderate asthma subjects.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Criteria
Inclusion Criteria:- Men and women of non-childbearing potential with mild to moderate asthma as defined by
forced expiratory volume in 1 second (FEV1) greater than 70% predicted.
- Well controlled asthma, as exhibited by completion of asthma questionnaire.
- Otherwise healthy, except for asthma.